Heterologous prime-boost with AdC68- and mRNA-based COVID-19 vaccines elicit potent immune responses in mice  

作　　者：Wenjuan Li Xingxing Li Danhua Zhao Jingjinq Liu Ling Wang Miao Li Xinyu Liu Jia Li Xiaohong Wu Yuhua Li 

机构地区：[1]Department of Arboviral Vaccine,National Institutes for Food and Drug Control,102629 Beijing,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第1期25-27,共3页信号转导与靶向治疗（英文）

摘　　要：Dear Editor An optimal vaccination program that can elicit Iong-lasting humoral and cellular immune response is key to Iong-term prevention of coronavirus disease 2019(COVID-19).Multiple variants of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)continue to emerge.The neutralizing capacities of available COVID-19 vaccines against these variants have declined.^(1) In such a scenario,heterologous prime-boost programs for COVID-19 vaccines have attracted considerable interest.

关 键 词：vaccines PREVENTION ACUTE 

分 类 号：R186[医药卫生—流行病学]